TG Therapeutics Inc (TGTX)
Activity ratios
Short-term
Turnover ratios
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 2.09 | 2.00 | 1.88 | 3.36 | 3.51 | 3.16 | 2.85 | — | — | — | 29.82 | — | — | — | 16.77 | — | — | — | — | — |
| Receivables turnover | 2.27 | 4.07 | 4.31 | 4.35 | 4.60 | 1.08 | 0.73 | — | — | 79.10 | 8.76 | 4.82 | 3.18 | 2.59 | 1.18 | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 0.58 | 1.21 | 1.07 | 0.84 | 0.69 | 0.14 | 0.05 | 0.02 | 0.03 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
The inventory turnover for TG Therapeutics Inc has ranged from 1.88 to 3.51 over the past eight quarters, indicating a consistent level of efficiency in managing inventory. There was a notable spike in inventory turnover in the first quarter of 2022, with a ratio of 29.82, potentially due to a decrease in inventory levels or an increase in sales during that period.
The receivables turnover ratio has shown significant variability, ranging from 0.73 to 79.10. This suggests fluctuations in the efficiency of collecting receivables, with particularly high turnover in the third quarter of 2022 and relatively lower turnover in the second and third quarters of 2023.
There is no data available for payables turnover, indicating a lack of information on how efficiently the company is managing its trade payables.
The working capital turnover ratio has also fluctuated, from 0.00 to 1.21, indicating variability in the efficiency of generating revenue relative to the working capital employed. Notably, there was a sharp increase in the second quarter of 2024, suggesting an improvement in utilizing working capital to generate sales during that period.
Overall, the activity ratios of TG Therapeutics Inc show varying levels of efficiency in managing inventory, collecting receivables, and utilizing working capital over the past quarters, highlighting the importance of monitoring these ratios for insights into the company's operational performance.
Average number of days
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 174.33 | 182.77 | 194.48 | 108.50 | 104.08 | 115.38 | 128.09 | — | — | — | 12.24 | — | — | — | 21.77 | — | — | — | — | — |
| Days of sales outstanding (DSO) | days | 161.00 | 89.60 | 84.63 | 83.87 | 79.34 | 338.10 | 497.14 | — | — | 4.61 | 41.66 | 75.79 | 114.65 | 140.77 | 310.27 | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Days of inventory on hand (DOH) for TG Therapeutics Inc have been fluctuating over the periods analyzed, ranging from as low as 12.24 days to as high as 194.48 days. The company's inventory turnover seems to vary significantly, indicating potential inefficiencies in managing inventory levels.
Days of sales outstanding (DSO) have also displayed significant variability, with values ranging from 4.61 days to 497.14 days. This suggests inconsistencies in the company's ability to collect receivables promptly, with longer DSO periods potentially impacting cash flow.
The lack of data for the number of days of payables prevents a comprehensive analysis of the company's overall working capital management efficiency. However, based on the available information, it appears that there may be room for improvement in optimizing payment timelines to suppliers.
Overall, TG Therapeutics Inc may benefit from refining its inventory management practices to reduce DOH, enhancing receivables collection processes to lower DSO, and potentially streamlining payables management to optimize working capital efficiency.
Long-term
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | 4,246.27 | 2,340.45 | 1,360.02 | 91.63 | 26.71 | 9.07 | 13.36 | 15.57 | 15.04 | 11.15 | 7.34 | 4.04 | 1.86 | 0.32 | 0.40 | 0.46 | 0.48 | 0.54 |
| Total asset turnover | 0.45 | 0.85 | 0.75 | 0.67 | 0.55 | 0.09 | 0.03 | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
TG Therapeutics Inc has shown a significant improvement in its fixed asset turnover ratio over the years, indicating the company's ability to efficiently generate sales from its fixed assets. The sharp increase in the fixed asset turnover from 91.63 in Jun 2023 to 4,246.27 in Mar 2024 is remarkable and could be attributed to better utilization of fixed assets or potentially significant capital investment during that period.
On the other hand, the total asset turnover ratio has fluctuated over the years, with a general upward trend from 0.00 in Dec 2020 to 0.85 in Jun 2024, suggesting an improvement in the company's overall efficiency in generating sales from its total assets.
The upward trend in both ratios reflects a positive sign for TG Therapeutics Inc's long-term activity efficiency, especially in utilizing its assets to generate revenue. However, it is essential to continue monitoring these ratios to ensure sustainable growth and efficient asset management.